Pyridopyrimidinones as Cryptosporidium parvum Calcium Dependent Protein Kinase 1 (CpCDPK1) Inhibitors

Simple item page
dc.contributor.advisorCuny, Gregory D.
dc.contributor.committeeMemberBeyda, Nicholas D.
dc.contributor.committeeMemberHu, Ming
dc.contributor.committeeMemberTrivedi, Meghna V.
dc.contributor.committeeMemberWilliams, Louis
dc.creatorWaldron-Young, Elise Marie
dc.date.accessioned2022-06-18T01:04:24Z
dc.date.createdDecember 2021
dc.date.issued2021-12
dc.date.submittedDecember 2021
dc.date.updated2022-06-18T01:04:25Z
dc.description.abstractCryptosporidium parvum, Cp, is a protozoan parasite that can cause life-threatening diarrhea. Given that only one drug is currently FDA approved for the treatment of cryptosporidiosis but with only limited efficacy, new medications are needed. In this dissertation compounds directed towards tRNA synthetase and calcium dependent protein kinase 1 (CDPK1), two promising molecular targets in the field, were assessed. In the case of tRNA synthetase, a collection of previously identified eukaryotic and prokaryotic tRNA synthetase inhibitors were screened for Cp growth inhibition in HCT-8 host cells. Three compounds, halofuginone, borrelidin and AN3661, were found to potently block Cp growth. A limited structure-activity relationship (SAR) analysis of AN3361 found that the propionic acid moiety present in the compound is critical for potent anti-Cryptosporidium activity. In the case of CpCDPK1, a diversified set of known protein kinases inhibitors were similarly assessed for Cp growth inhibition. This exercise identified pyridopyrimidones as a new chemotype of potent Cp growth inhibitors that were confirmed to block CpCDPK1 kinase activity. SAR analysis provided further insights into two structural features for achieving potent CpCDPK1 kinase and Cp growth inhibition, namely appropriate occupancy of the ATP binding pocket near the C-helix and the presence of a hydrogen bond acceptor in the solvent exposed portion of the inhibitor. A promising derivative, UH15_16, potently inhibited Cp growth (EC50 = 14 nM) and CpCDPK1 kinase (IC50 = 5.4 nM) activities, as well as displayed moderate selectivity based on kinase profiling. UH15_16 formulated as a 2:1 mixture with Captisol® in water demonstrated limited systemic exposure following oral administration, was well tolerated at 50 mg/kg once per day dosing for 5 days in mice and resulted in a 75% reduced burden of the gut pathogen at 50 mg/kg once per day dosing for 7 days in an acute mouse model of cryptosporidiosis. The third formulation (5x Captisol with 2% Tween 80 at double the volume in water), dosed 25 mg/kg BID, resulted in a safe toxicity profile and a 74% reduction of the gut pathogen when dosed for 7 days in the same model
dc.description.departmentPharmacological and Pharmaceutical Sciences, Department of
dc.format.digitalOriginborn digital
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://hdl.handle.net/10657/9308
dc.language.isoeng
dc.rightsThe author of this work is the copyright owner. UH Libraries and the Texas Digital Library have their permission to store and provide access to this work. Further transmission, reproduction, or presentation of this work is prohibited except with permission of the author(s).
dc.subjectCryptosporidium, CpCDPK1 inhibitors
dc.titlePyridopyrimidinones as Cryptosporidium parvum Calcium Dependent Protein Kinase 1 (CpCDPK1) Inhibitors
dc.type.dcmiText
dc.type.genreThesis
dcterms.accessRightsThe full text of this item is not available at this time because the student has placed this item under an embargo for a period of time. The Libraries are not authorized to provide a copy of this work during the embargo period.
local.embargo.lift2023-12-01
local.embargo.terms2023-12-01
thesis.degree.collegeCollege of Pharmacy
thesis.degree.departmentPharmacological and Pharmaceutical Sciences, Department of
thesis.degree.disciplinePharmaceutics
thesis.degree.grantorUniversity of Houston
thesis.degree.levelDoctoral
thesis.degree.nameDoctor of Philosophy

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
WALDRON-YOUNG-DISSERTATION-2021.pdf
Size:
6.55 MB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 2 of 2
No Thumbnail Available
Name:
PROQUEST_LICENSE.txt
Size:
4.43 KB
Format:
Plain Text
Description:
Download
No Thumbnail Available
Name:
LICENSE.txt
Size:
1.82 KB
Format:
Plain Text
Description:
Download

Collections

Published ETD Collection